IL250321B - Anti-ctla4 monoclonal antibody or its conjugated antigen residue, pharmaceutical composition and uses - Google Patents

Anti-ctla4 monoclonal antibody or its conjugated antigen residue, pharmaceutical composition and uses

Info

Publication number
IL250321B
IL250321B IL250321A IL25032117A IL250321B IL 250321 B IL250321 B IL 250321B IL 250321 A IL250321 A IL 250321A IL 25032117 A IL25032117 A IL 25032117A IL 250321 B IL250321 B IL 250321B
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
monoclonal antibody
conjugated antigen
ctla4 monoclonal
antigen residue
Prior art date
Application number
IL250321A
Other languages
Hebrew (he)
Other versions
IL250321A0 (en
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of IL250321A0 publication Critical patent/IL250321A0/en
Publication of IL250321B publication Critical patent/IL250321B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL250321A 2014-08-01 2017-01-26 Anti-ctla4 monoclonal antibody or its conjugated antigen residue, pharmaceutical composition and uses IL250321B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410377352.9A CN105296433B (en) 2014-08-01 2014-08-01 A kind of CTLA4 antibody, its medical composition and its use
PCT/CN2015/085721 WO2016015675A1 (en) 2014-08-01 2015-07-31 Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use

Publications (2)

Publication Number Publication Date
IL250321A0 IL250321A0 (en) 2017-03-30
IL250321B true IL250321B (en) 2021-06-30

Family

ID=55194268

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250321A IL250321B (en) 2014-08-01 2017-01-26 Anti-ctla4 monoclonal antibody or its conjugated antigen residue, pharmaceutical composition and uses

Country Status (39)

Country Link
US (4) US10449251B2 (en)
EP (2) EP3176181B1 (en)
JP (2) JP6514774B2 (en)
KR (1) KR102017396B1 (en)
CN (3) CN105296433B (en)
AP (1) AP2017009762A0 (en)
AU (2) AU2015295936C1 (en)
CA (1) CA2956000C (en)
CL (1) CL2017000250A1 (en)
CO (1) CO2017000754A2 (en)
CR (1) CR20170033A (en)
CY (1) CY1124190T1 (en)
DK (1) DK3176181T3 (en)
DO (1) DOP2017000031A (en)
EA (1) EA036396B1 (en)
EC (1) ECSP17012781A (en)
ES (1) ES2857509T3 (en)
GE (2) GEAP202014437A (en)
HR (1) HRP20210448T1 (en)
HU (1) HUE053719T2 (en)
IL (1) IL250321B (en)
LT (1) LT3176181T (en)
MA (2) MA40474B1 (en)
MD (1) MD4795C1 (en)
MX (2) MX387685B (en)
MY (1) MY192822A (en)
NI (1) NI201700008A (en)
NZ (1) NZ729158A (en)
PE (1) PE20170772A1 (en)
PH (1) PH12017500190B1 (en)
PL (1) PL3176181T3 (en)
PT (1) PT3176181T (en)
RS (1) RS61590B1 (en)
SG (1) SG11201700819QA (en)
SI (1) SI3176181T1 (en)
TN (1) TN2017000010A1 (en)
UA (1) UA119570C2 (en)
WO (1) WO2016015675A1 (en)
ZA (1) ZA201700528B (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
CN105296433B (en) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 A kind of CTLA4 antibody, its medical composition and its use
DK3303394T3 (en) 2015-05-29 2020-07-06 Agenus Inc ANTI-CTLA-4 ANTIBODIES AND PROCEDURES FOR USE THEREOF
JP6869987B2 (en) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド Anti-PD-1 antibody and how to use it
TW201735949A (en) 2016-03-24 2017-10-16 千禧製藥公司 Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
MA44483A (en) 2016-03-24 2019-01-30 Millennium Pharm Inc METHODS FOR TREATING GASTROINTESTINAL ADVERSE EVENTS OF IMMUNE ORIGIN IN ONCOLOGICAL IMMUNE TREATMENTS
CN107400166A (en) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 for CTLA4 single domain antibody and its derived protein
KR102379464B1 (en) 2016-06-20 2022-03-29 키맵 리미티드 anti-PD-L1 antibody
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (en) 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
CN106967172B (en) * 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
JP6976322B2 (en) * 2016-10-10 2021-12-08 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） New anti-CTLA4 antibody
KR20230133934A (en) 2016-10-11 2023-09-19 아게누스 인코포레이티드 Anti-lag-3 antibodies and methods of use thereof
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
JP2020513819A (en) * 2017-03-15 2020-05-21 スージョウ ギャラクシー バイオファーマ カンパニー リミテッド CTLA4 antibody, pharmaceutical composition and use thereof
CN110505882A (en) * 2017-03-31 2019-11-26 默沙东公司 Compositions and methods for treating cancer with a combination of an antagonist of PD-1 and an anti-CTLA4 antibody
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN110913906A (en) 2017-05-02 2020-03-24 默沙东公司 Preparation of anti-LAG3 antibody and co-formulation of anti-LAG3 antibody and anti-PD-1 antibody
CA3060695A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN108948194B (en) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 A new CTLA-4 monoclonal antibody
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
IL270743B2 (en) * 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to lymphocyte-associated protein - Tcytotoxic 4 (CTLA-4), preparations containing them and their uses
CN107325181A (en) * 2017-07-05 2017-11-07 无锡傲锐东源生物科技有限公司 Anti-CTLA 4 protein monoclonal antibody and application thereof
CN111511762B (en) 2017-08-21 2025-05-06 天演药业公司 Anti-CD 137 molecules and uses thereof
CA3073984A1 (en) * 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CN119792515A (en) * 2018-02-13 2025-04-11 默沙东有限责任公司 Method for treating cancer using anti-PD-1 antibody and anti-CTLA-4 antibody
WO2019179388A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-ctla-4 antibody polypeptide
CN109336975B (en) * 2018-04-18 2022-05-13 中国科学院微生物研究所 PD-1-targeted tumor inhibitory antibody and application thereof
WO2019233413A1 (en) 2018-06-05 2019-12-12 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Dimer and use thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN110760002A (en) * 2018-07-25 2020-02-07 南京金斯瑞生物科技有限公司 Humanized anti-human CTLA4 monoclonal antibody and preparation method and application thereof
MX2021004356A (en) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulations of anti-rsv antibodies and methods of use thereof.
MA54089A (en) 2018-10-31 2022-02-09 Merck Sharp & Dohme HUMAN ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
JP7503056B6 (en) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー Co-formulation of anti-LAG3 and anti-PD-1 antibodies
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
BR112021012631A2 (en) 2018-12-26 2021-12-14 Xilio Dev Inc Anti-ctla4 antibodies and methods of using them
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MA55316A (en) 2019-03-13 2022-01-19 Merck Sharp & Dohme CANCER MULTI-THERAPIES INCLUDING CTLA-4 AND PD-1 BLOCKING AGENTS
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
TWI888925B (en) * 2019-06-10 2025-07-01 英屬開曼群島商天演藥業有限公司 Anti-ctla4 antibodies and methods of making and using the same
CN110256561B (en) * 2019-06-13 2021-04-16 东大生物技术(苏州)有限公司 Group of CTLA-4 monoclonal antibodies and medical application thereof
CN110256563A (en) * 2019-07-05 2019-09-20 石河子大学 CTLA-4 nanobody, preparation method and application thereof
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
TW202136287A (en) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 Bifunctional molecules comprising an il-7 variant
JP2023515675A (en) * 2020-03-05 2023-04-13 メルク・シャープ・アンド・ドーム・エルエルシー Methods of treating cancer using a combination of a PD-1 antagonist, a CTLA4 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof
WO2021178611A1 (en) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody
US12559565B2 (en) 2020-04-13 2026-02-24 Biosion Inc. Antibodies binding CTLA4 and uses thereof
US12595307B2 (en) 2020-06-11 2026-04-07 Nantbio, Inc. Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
CN113980130B (en) * 2020-07-27 2023-07-21 湖南远泰生物技术有限公司 Humanized CD37 and bispecific CD19-humanized CD37 CAR-T cells
CN112079926A (en) * 2020-09-17 2020-12-15 北京华大蛋白质研发中心有限公司 Anti-human CTLA4 monoclonal antibody and application thereof
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (en) 2021-04-09 2024-01-08 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties.
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN117069850B (en) * 2021-12-20 2025-02-14 南京诺唯赞检测技术有限公司 A monoclonal antibody of VCE and preparation method thereof
CN118541390A (en) * 2022-01-30 2024-08-23 百奥赛图(北京)医药科技股份有限公司 Anti-CTLA4/OX40 bispecific antibodies and uses thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
TW202426499A (en) * 2022-09-16 2024-07-01 大陸商同潤生物醫藥(上海)有限公司 PH-dependent anti-CTLA4 antibody or antigen-binding fragment
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN115960266A (en) * 2022-12-13 2023-04-14 广西医科大学附属肿瘤医院 Cytokine fusion nanobody CTLA-4 Nb16-IL12 and preparation method and application thereof
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (en) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス Lipid-based nanoparticles targeted to activated immune cells for the expression of immune cell-enhancing molecules and their use
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US682736A (en) 1900-08-02 1901-09-17 James C Owen Oil-can.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
CA2219202A1 (en) 1995-04-27 1996-10-31 Advanced Tissue Sciences, Inc. Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing tissue, synthetic or native vascular grafts
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (en) 1998-12-23 2019-03-29 Pfizer Human monoclonal antibodies for CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
KR100945108B1 (en) * 2001-06-13 2010-03-02 젠맵 에이/에스 Human Monoclonal Antibodies to Epidermal Growth Factor Receptor (EVF)
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
EP1513794B1 (en) 2002-05-24 2013-03-06 Castrol Limited Preparation of monomers for grafting to polyolefins, and lubricating oil compositions containing grafted copolymer
DE60334303D1 (en) 2002-07-03 2010-11-04 Tasuku Honjo IMMUNO-POTENTIAL COMPOSITIONS
JP2006500931A (en) 2002-09-30 2006-01-12 ファイザー・プロダクツ・インク Hybridoma producing high level human sequence antibodies
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
KR100944575B1 (en) * 2002-10-17 2010-02-25 젠맵 에이/에스 Human monoclonal antibodies against CD20
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
KR100845354B1 (en) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 Use of anti-CTLA-4 antibody
DE102004063494A1 (en) * 2004-12-23 2006-07-13 Tegenero Ag antibody
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
WO2006110277A1 (en) 2005-04-11 2006-10-19 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN101074264B (en) * 2006-05-17 2011-08-17 上海抗体药物国家工程研究中心有限公司 Recombinant anti-CTLA4 monoclonal antibody, its production and use
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
DK2501822T3 (en) 2009-11-17 2017-11-27 Squibb & Sons Llc PROCEDURES FOR IMPROVED PROTEIN PRODUCTION
CN102134276A (en) * 2010-01-22 2011-07-27 上海抗体药物国家工程研究中心有限公司 Chimeric antibody resisting CTLA-4 (Cytotoxic T Lymphocyte Antigen)
RU2013118723A (en) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой ONCOLITIC Adenovirus VECTORS CODING MONOCLONAL ANTIBODIES AGAINST CTLA-4
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
RU2657440C2 (en) 2011-06-30 2018-06-13 Джензим Корпорейшн Inhibitors of t-cell activation
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US8844207B2 (en) 2012-06-04 2014-09-30 Mity-Lite, Inc. Portable dance floor panel with floating magnet retention system
CN102801616B (en) 2012-08-02 2015-04-15 华为技术有限公司 Message sending and receiving method, device and system
EP2759305A1 (en) 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3114144A1 (en) 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2017515859A (en) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Treatment of lung cancer using a combination of anti-PD-1 antibodies and other anticancer agents
CN105296433B (en) 2014-08-01 2018-02-09 中山康方生物医药有限公司 A kind of CTLA4 antibody, its medical composition and its use
WO2016100561A2 (en) 2014-12-16 2016-06-23 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
CN104479019B (en) 2014-12-26 2020-07-21 上海复宏汉霖生物技术股份有限公司 An anti-CTLA-4 human antibody
KR102672113B1 (en) 2015-02-16 2024-06-03 론자 리미티드 Antibodies for CL and/or CH1 mutated drug conjugation
WO2016183469A1 (en) 2015-05-13 2016-11-17 Robert Kirken Anti-ctla-4 blockade
EP3408296A1 (en) 2016-01-27 2018-12-05 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent

Also Published As

Publication number Publication date
PT3176181T (en) 2021-03-04
MA40474B1 (en) 2021-02-26
US20260166139A1 (en) 2026-06-18
PH12017500190B1 (en) 2022-07-20
KR20170036092A (en) 2017-03-31
JP2017523807A (en) 2017-08-24
BR112017002080A2 (en) 2018-02-27
LT3176181T (en) 2021-04-12
CN106687479A (en) 2017-05-17
HUE053719T2 (en) 2021-07-28
EA036396B1 (en) 2020-11-05
MD4795C1 (en) 2022-09-30
MX387685B (en) 2025-03-18
ECSP17012781A (en) 2017-08-31
GEP20207166B (en) 2020-10-12
IL250321A0 (en) 2017-03-30
AU2018247270A1 (en) 2018-11-01
EP3176181A1 (en) 2017-06-07
AU2015295936C1 (en) 2019-08-01
NZ729158A (en) 2020-03-27
MX2021013586A (en) 2021-12-10
US10449251B2 (en) 2019-10-22
AP2017009762A0 (en) 2017-02-28
EA201790288A1 (en) 2017-06-30
DK3176181T3 (en) 2021-03-08
PE20170772A1 (en) 2017-07-04
US20200206346A1 (en) 2020-07-02
AU2015295936B2 (en) 2018-11-08
MD20170022A2 (en) 2017-06-30
SI3176181T1 (en) 2021-07-30
CL2017000250A1 (en) 2017-08-18
MY192822A (en) 2022-09-12
CN106687479B (en) 2022-10-25
CN106687479A8 (en) 2017-07-07
JP6783886B2 (en) 2020-11-11
CN105296433A (en) 2016-02-03
RS61590B1 (en) 2021-04-29
ZA201700528B (en) 2022-11-30
EP3858861A1 (en) 2021-08-04
US20170216433A1 (en) 2017-08-03
ES2857509T3 (en) 2021-09-29
UA119570C2 (en) 2019-07-10
MD4795B1 (en) 2022-02-28
KR102017396B1 (en) 2019-09-02
CN105296433B (en) 2018-02-09
CA2956000C (en) 2022-09-27
MX2017001446A (en) 2017-12-15
US11291720B2 (en) 2022-04-05
US20230064544A1 (en) 2023-03-02
GEAP202014437A (en) 2020-06-10
CN115960232B (en) 2026-05-26
US12447208B2 (en) 2025-10-21
MA55868A (en) 2022-04-06
MA40474A (en) 2017-06-07
CR20170033A (en) 2017-09-29
EP3176181B1 (en) 2020-12-23
JP6514774B2 (en) 2019-05-15
EP3176181A4 (en) 2018-03-14
WO2016015675A1 (en) 2016-02-04
CA2956000A1 (en) 2016-02-04
CO2017000754A2 (en) 2017-06-30
PL3176181T3 (en) 2021-07-26
HRP20210448T1 (en) 2021-05-28
TN2017000010A1 (en) 2018-07-04
PH12017500190A1 (en) 2017-06-28
JP2019107018A (en) 2019-07-04
NI201700008A (en) 2017-03-08
AU2015295936A1 (en) 2017-03-09
SG11201700819QA (en) 2017-03-30
DOP2017000031A (en) 2017-07-15
CN115960232A (en) 2023-04-14
CY1124190T1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
EP3325513B1 (en) Anti-PD-L1 antibodies and their uses
IL290842A (en) Anti-cd73 antibodies and uses thereof
ZA202000113B (en) Anti-ctla-4 antibodies and uses thereof
FR25C1022I2 (en) ANTI-PD-1 ANTIBODIES
IL267070A (en) Anti-ox40 antibodies and their uses
HUE053719T2 (en) Monoclonal antibody or antigen-binding fragment thereof against CTLA4, pharmaceutical composition and use
HUE051700T2 (en) Anti-PD-1 antibodies
EP3571231A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
DK3541841T3 (en) Anti-PD-1 Antibodies and Compositions
PL3505535T3 (en) ANTI-PD1 MONOCLONAL ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND ITS USE
DK3441086T3 (en) Monoclonal anti-PD-1 antibody
DK3368572T3 (en) ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
IL291545A (en) Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses
DK3455257T3 (en) ANTI-PD-L1 ANTIBODIES
LT3303394T (en) ANTI-CTLA-4 ANTIBODIES AND THEIR USES
EP3426686C0 (en) HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
PT3443009T (en) ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
SG10201603721TA (en) Anti-CTLA-4 Antibodies
DK3649152T3 (en) ROR1 antibodies
DK3332006T3 (en) Novel anti-PD-L1 antibodies
EP3383915A4 (en) ANTI-PD-1 ANTIBODIES
IL274502A (en) Anti-ox40 antibodies and uses thereof
EP3567053A4 (en) MONOCLONAL ANTI-CLAUDIN-2 ANTIBODY
EP3498838A4 (en) ANTI-PD-L1 ANTIBODIES
EP3498839A4 (en) ANTI-PD-1 ANTIBODIES

Legal Events

Date Code Title Description
FF Patent granted